Recursion Pharmaceuticals, Inc. RXRX
Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. 10-K, Item 1
- Headquarters
- Salt Lake City, UT
- CEO
- Najat Khan
- Next results
- around Feb 24, 2027
RXRX among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
14 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 25, 2026 against Feb 28, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 7 checks found nothing to note
-
Critical audit matters changedNew this year: External Research and Development Expenses (“As described in Note 2 to the consolidated financial statements, research and development expenses comprise of costs incurred in performing research and development activities (other than those performed pursuant to contracts with customers, which are recorded as revenue), including drug discovery a”). No longer listed: Acquisition of Exscientia plc - Valuation of Platform Technology and In-Process Research and Development
-
Material weakness in internal control“Further, in connection with the business combination with Exscientia, material weaknesses related to internal controls over financial reporting were identified related to ineffective process and controls, which resulted in an immaterial misstatement to unearned revenue and unearned revenue, non-current in our consolidated financial statements as of and for the year ended December 31, 2024, which remain unremediated as of December 31, 2025 (see “Part II - Item 9A - Controls and Procedures” for fu”
-
Cash from operations −$371.8M vs net income −$644.8M (FY ending Dec 31, 2025)
6 more checks with nothing to note
-
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
14 paragraphs in Risk Factors that were not in the 10-K filed Feb 28, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
Increasing scrutiny and changing expectations from governments, regulators, and third-parties relating to environmental, social and governance (ESG) policies and practices may cause us to incur additional costs, expose us to additional risks or impact our reputation. In recent years, there has been increasing public focus and scrutiny…
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
We currently have operations in the United States (Salt Lake City and New York), The United Kingdom (London and Milton Park) and Canada (Montreal). While these locations are in or near major biotechnology and technology hubs,
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
If we achieve success in our clinical trials, we would need to scale our operations to support commercialization, and we may encounter difficulties in managing this growth. While we do not anticipate significant growth in our workforce or the scope of our operations in the near-term, our long-term strategy depends on the successful…
-
Item 1A · new paragraph · not in the 10-K filed Feb 28, 2025 10-K, ITEM 1A
We may acquire additional businesses, products, form strategic alliances, or create joint ventures and we may not realize the benefits of such transactions.
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $39.8M | $44.6M | $58.8M | $74.7M |
| Net income | −$239.5M | −$328.1M | −$463.7M | −$644.8M |
| Operating cash flow | −$83.5M | −$287.8M | −$359.2M | −$371.8M |
| Free cash flow | −$120.6M | −$299.7M | −$372.9M | −$378.3M |
Revenue, FY2019 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$74.7M ▲ 26.9% in FY2025−$644.8M in FY2025−$378.3M in FY2025
Recent filings
3 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 3, 2026Borgeson Blake (Director) gave notice of a planned sale of 40,000 shares worth about $155K Form 144, approximate sale date Nov 3, 2026, under a 10b5-1 plan adopted Aug 31, 2025
-
8-KNov 2, 2026Quarterly results, Director or officer change, Regulation FD disclosure 8-K items 2.02, 5.02, 7.01
-
10-QNov 2, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Recursion Pharmaceuticals, Inc., Salt Lake City, UT · from the 10-K filed Feb 25, 2026
Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS). This platform provides end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. All of our technologies are designed to translate complex science into medicines that matter - faster, better, and at scale - for patients who are waiting.
- Headquarters
- Salt Lake City, UT
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 2, 2026
- Incorporated in
- DE
Email alerts
Sources
The 10-K filed Feb 25, 2026 (open at SEC), compared with the 10-K filed Feb 28, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RXRX/export.csv") into a cell.